Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation

被引:170
作者
Gill, AL
Frederickson, M
Cleasby, A
Woodhead, SJ
Carr, MG
Woodhead, AJ
Walker, MT
Congreve, MS
Devine, LA
Tisi, D
O'Reilly, M
Seavers, LCA
Davis, DJ
Curry, J
Anthony, R
Padova, A
Murray, CW
Carr, RAE
Jhoti, H
机构
[1] Astex Technol, Med Chem Grp, Cambridge CB4 0QA, England
[2] Astex Technol, Prot Struct Grp, Cambridge CB4 0QA, England
[3] Astex Technol, Prot Technol Grp, Cambridge CB4 0QA, England
[4] Astex Technol, Bio Grp, Cambridge CB4 0QA, England
[5] Astex Technol, Comp Chem & Informat Grp, Cambridge CB4 0QA, England
关键词
D O I
10.1021/jm049575n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We describe the structure-guided optimization of the molecular fragments 2-amino-3-benzyl-oxypyridine 1 (IC50 1.3 mM) and 3-(2-(4-pyridyl)ethyl)indole 2 (IC50 35 muM) identified using X-ray crystallographic screening of p38alpha. MAP kinase. Using two separate case studies, the article focuses on the key compounds synthesized, the structure-activity relationships and the binding mode observations made during this optimization process, resulting in two potent lead series that demonstrate significant increases in activity. We describe the process of compound elaboration either through the growing out from fragments into adjacent pockets or through the conjoining of overlapping fragments and demonstrate that we have exploited the mobile conserved activation loop, consisting in part of Asp168-Phe169-Gly170 (DFG), to generate significant improvements in potency and kinase selectivity.
引用
收藏
页码:414 / 426
页数:13
相关论文
共 41 条
[1]  
Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   High-throughput crystallography for lead discovery in drug design [J].
Blundell, TL ;
Jhoti, H ;
Abell, C .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :45-54
[4]  
BRISTOL JA, 1981, SYNTHESIS-STUTTGART, P971
[5]   FREE R-VALUE - A NOVEL STATISTICAL QUANTITY FOR ASSESSING THE ACCURACY OF CRYSTAL-STRUCTURES [J].
BRUNGER, AT .
NATURE, 1992, 355 (6359) :472-475
[6]   Structure-based screening of low-affinity compounds [J].
Carr, R ;
Jhoti, H .
DRUG DISCOVERY TODAY, 2002, 7 (09) :522-527
[7]   Cytokines in rheumatoid arthritis: trials and tribulations [J].
Carteron, NL .
MOLECULAR MEDICINE TODAY, 2000, 6 (08) :315-323
[8]   Inhibitors of p38α MAP kinase [J].
Chakravarty, S .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37, 2002, 37 :177-186
[9]  
Cirillo Pier F., 2002, Current Topics in Medicinal Chemistry, V2, P1021, DOI 10.2174/1568026023393390
[10]   Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor [J].
Dumas, J ;
Hatoum-Mokdad, H ;
Sibley, RN ;
Smith, RA ;
Scott, WJ ;
Khire, U ;
Lee, W ;
Wood, J ;
Wolanin, D ;
Cooley, J ;
Bankston, D ;
Redman, AM ;
Schoenleber, R ;
Caringal, Y ;
Gunn, D ;
Romero, R ;
Osterhout, M ;
Paulsen, H ;
Housley, TJ ;
Wilhelm, SM ;
Pirro, J ;
Chien, DS ;
Ranges, GE ;
Shrikhande, A ;
Muzsi, A ;
Bortolon, E ;
Wakefield, J ;
Ostravage, CG ;
Bhargava, A ;
Chau, T .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (12) :1559-1562